MDM4 and breast cancer: Principal-component analysis (PCA) of all mRNA-Seq data from BC-3/Cas9 clearly showed that the MDM4 KO expression profiles at day 16 (∼50% viability) were distinct from those of IRF4 or BATF KO cells (Fig. S8C).